Dose Escalation Study of ARQ 736 in Adult Subjects With Advanced Solid Tumors Harboring BRAF and/or NRAS Mutations
Clinical trial NCT01225536 · COMPLETED
Trial details
- NCT number
- NCT01225536
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2010-10-01
- Primary completion
- 2013-01-01
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.